Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors
Completed · Phase 1
Conditions studied: Cardiovascular Disease
In brief
Rationale: Survivors of childhood cancer are at an increased risk of developing cardiovascular risk factors as well as early cardiovascular disease, likely due to the intensive therapeutic regimen used to treat their cancer. Purple grape juice (PGJ) is a rich source of flavonoids and a powerful antioxidant. Clinical studies in both diseased and healthy adults suggest that daily consumption of PGJ contributes to increased antioxidant capacity, reduced low-density lipoprotein (LDL) oxidation, and improved vasodilation. Purpose: This randomized clinical trial is evaluating whether purple grape juice can reduce oxidative stress and improve the vascular health of survivors of childhood cancer in the early stages of cardiovascular disease.
Key facts
- Study ID
- NCT01043939
- Run by
- University of Minnesota
- People needed
- 24
- Starts
- 2009-11-01
- Expected to finish
- 2010-12-01
- Last updated by the study team
- 2014-12-31
Who can join
Age: 10 and older, up to 30. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosed with cancer > 5 years ago
- Off-maintenance therapy for > 36 months
- Age 10-30 years
- Reside within a 50 mile radius of the University of Minnesota
You may not qualify if…
- Pregnant or planning to become pregnant
- Start of oral contraceptives < or = 3 months prior to study enrollment
- Current smoker
- Diabetes (type 1 and 2)
- Antibiotic use < 2 weeks prior to study enrollment
Where it is running
- Minnesota General Clinical Research Center — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.